ROPIVACAINE ALTAN 10 mg/ml, solution for injection 5 ampoules of 10 ml
Active ingredients: Ropivacaine hydrochloride, (S)-N-(2,6-dimethylphenyl)-1-ethylpiperidine-2-carboxamide
Commercialized according to BDPMDispensing in France: Prescription only, hospital use
Solution for injection5 ampoules of 10 mlinfiltration;péridurale;périneurale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- ROPIVACAINE ALTAN 10 mg/mL, solution injectable
- Pharmaceutical form
- solution injectable
- Route of administration
- infiltration;péridurale;périneurale
- Presentation description
- 5 ampoules en verre de 10 mL
- Marketing authorisation holder
- ALTAN PHARMACEUTICALS (ESPAGNE)
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 31 Aug 2022
- Prescription and dispensing conditions
- Prescription only, hospital use
- List II: prescription-only medicine
- Hospital use only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
60105568CIP75506197CIP133400955061977Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| CHLORHYDRATE DE ROPIVACAÏNE MONOHYDRATÉsolution | — | SA |
| CHLORHYDRATE DE ROPIVACAÏNEsolution | 10 mg · 1 mL de solution | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.